Key Takeaways: Semaglutide is the active ingredient in both Ozempic and Wegovy, working by mimicking GLP-1 to reduce appetite and improve blood sugar control. Wegovy (higher-dose semaglutide) is FDA-approved for weight loss, while Ozempic is primarily approved for type 2 diabetes but often used off-label. Clinical trials show semaglutide can lead to ~15% body weight loss over ~68 weeks when combined with lifestyle changes. Ozempic typically produces slightly lower average weight loss due to its lower maximum dose, though results can still be significant. Gradual tapering off semaglutide, combined with lifestyle support, may help reduce weight regain after stopping treatment. Long-term success depends on pairing medication with nutrition, physical activity, and ongoing medical guidance. Understanding the Basics Semaglutide is the active drug found in both Ozempic and Wegovy
Understanding GLP-1 Medications: GLP-1 receptor agonists work by mimicking a naturally occurring hormone, incretin, which stimulates insulin secretion and reduces appetite
ARTHRALGIA Severe and disabling arthralgia in patients taking DPP-4 inhibitors has been reported (281)
J Am Coll Cardiol (2001) 37:134450
Peptides work synergistically with proper nutrition, exercise, sleep, and stress managementnot as replacements for these fundamentals
This evidence typically includes: Detailed medical records documenting the timeline of Zepbound use and symptom onset Ophthalmological examinations and diagnostic imaging confirming the nature and extent of eye damage Expert medical testimony linking the vision complications to tirzepatide exposure Documentation of functional impairment and its impact on quality of life Importance of Timely Action The statute of limitations for filing such claims varies by jurisdiction, making prompt consultation with legal counsel essential for preserving ones rights to seek compensation for medical expenses, lost income, and diminished quality of life resulting from Zepbound-related vision complications
